A local physician is working with major pharmaceutical companies to bring drugs for Alzheimer’s and depression to the market to better serve those suffering from those illnesses.
Dr. Jeffrey Apter, a nationally renowned depression and Alzheimer’s specialist, is enrolling interested patients in clinical trials for Alzheimer’s and/or depression.
“There are many advantages to the patient who participates: free treatment, office visits and trial medications,” said Dr. Apter. “In many cases, participating in a clinical trial means the patient may benefit from the drug up to five years before it’s ultimately approved.”
Dr. Apter explains the drugs in his clinical trials are the next generation for treating these ailments. While there are several drugs currently on the market for Alzheimer’s, they treat only the symptoms. The drugs in Princeton Medical Institute’s clinical trials are called disease-modifying drugs and may prevent Alzheimer’s from progressing.
“We urge people to come in early, or if they are at high risk, as the chance of benefiting is higher,” he added. “Those with memory problems or forgetfulness out of proportion to their age –– in their early 50s, for example –– or those with mild or moderate Alzheimer’s may be candidates.”
Princeton Medical Institute uses sophisticated tests such as PET scans to look for excessive protein deposits in the brain, memory tests, and bio markers to identify people at risk, often years before they develop clinical symptoms. The trials are testing cutting-edge medications that may prevent the accumulation of a “bad” protein on the brain, and vaccinate against a specific antibody, as well.
“Depression also impacts a large part of our society: we’ve already done clinical trials on many of the drugs currently on the market,” Dr. Apter noted. “This new trial is testing a drug a patient would receive in addition to what he or she already is taking.”
People who are on medication for depression but currently are not responding or are not getting a robust response are good candidates. One of the drugs in trial is a triple re-uptake inhibitor, addressing serotonin, norepinephrine and dopamine, a significant difference from current anti-depressants.
"One thing that makes our trials different is that, although they are double-blind, once we’re finished with the study everyone participating gets the medication and the chance to benefit from it," Dr. Apter stated.
Dr. Apter emphasized that clinical trials are a real service to the public good. Not only do they test drugs to prepare them to come to market, but there also is a high level of medical attention given each participant, including a variety medical tests and office visits.
Princeton Medical Institute is looking for interested adults for its many clinical trials for drugs for Alzheimer’s, depression, smoking cessation and more. Those interested should call 609-921-6050 to see if they qualify.
Princeton Medical Institute, Woodlands Professional Building, 256 Bunn Drive, Suite 6, Princeton 08540. 609-921-6050. email@example.com. www.princetonmedicalinstitute.com